Genmab: Daratumumab caught everyone's eye once again

BUY, Fair Value Under Review

News published on June Monday 13, 2016
Share on

Details from the POLLUX study (which evaluated daratumumab in combination with Celgene’s Revlidmid (lenalidomide) and dexamethasone in relapsed/refractory patients with multiple myeloma) were presented yesterday at the EHA meeting; and let’s say the data were simply outstanding… And we will update our sales estimates accordingly. For the time being, we put our FV under (positive) review while reiterating our BUY recommendation.

For more information, please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities